Patients with advanced pancreatic cancer now have access to the new FDA
approved drug, Onivyde, that produced significant overall survival rates
in an international clinical study conducted in part by researchers at
Honor Health Research Institute and the Translational Genomics Research
Institute.
"Results from our clinical trial research showed a patient survival rate
of nearly two more months without decreasing the quality of life
compared to the other treatments tested," said Gayle Jameson, principal
investigator, NAPOLI-1 study and associate investigator, HonorHealth
Research Institute. "Invariably pancreatic cancer progresses at some
point and we don't have a universal standard of what to do next. In
this disease, two months of survival is a game changer for treating
advanced pancreatic cancer and gives patients hope." Onivyde, will be used as part of a combination regimen with a two-drug
chemotherapy. It was approved to treat patients with pancreatic cancer
that progressed after treatment with a different chemotherapy.
No comments:
Post a Comment